The physiological role of the pro-survival BCL-2 family member A1 has been debated for a long time. Strong mRNA induction in T cells on T cell receptor (TCR)-engagement suggested a major role of A1 in the survival of activated T cells. However, the investigation of the physiological roles of A1 was complicated by the quadruplication of the A1 gene locus in mice, making A1 gene targeting very difficult. Here, we used the recently generated A1
On antigenic challenge, T lymphocytes need to rapidly switch from their IL-7/IL-7R-regulated naive, quiescent state 1,2 to a T cell antigen-receptor (TCR/CD3) stimulation-induced activation state. 3 In case of inappropriate stimulation of the TCR, for example, in the absence of co-receptor stimulation, this shift in the survival programme is not induced and leads to rapid T cell death. 4 Conversely, appropriately stimulated T cells expand rapidly, allowing accumulation of T cell clones expressing TCRs of high affinity for specific antigens. During this clonal expansion, BCL-2 family regulated apoptosis acts as a mechanism to remove low-affinity T cells, thereby ensuring the generation of a highly effective immune response. 5 On infection clearance, most of the activated T cells are removed by apoptosis, 6 leaving only some T cells with antigen-specific high-affinity TCRs in reserve as longlived memory T cells. 7 The BCL-2 family of proteins regulate apoptotic cell death, with the balance between pro-survival and pro-apoptotic family members determining whether a cell lives or dies. The expression of pro-survival BCL-2 family members is dynamically regulated during T cell activation. 8 TCR/CD3 ligation leads to the downregulation of BCL-2 and induction of BCL-XL. 3 Accordingly, Bcl-2 −/− mice display a loss of mature, unstimulated T cells, and the death of these cells can be prevented by TCR/CD3 stimulation. 9 Interestingly, although BCL-XL is substantially upregulated on TCR/CD3 stimulation, its loss did not increase apoptosis or impair proliferation of T cells stimulated with mitogenic antibodies. 10 In contrast, MCL-1 has been shown to be a crucial pro-survival factor after T cell activation. 11, 12 A1 is a prosurvival BCL-2 family protein that has been proposed to be important for activated T cell survival based on its expression status in different T cell subsets. In naive T cells, A1 protein is hardly detectable, but its expression is strongly and rapidly induced on TCR/CD3 stimulation. 3, 13 Addressing the physiological role of A1 in mice has been difficult due to a quadruplication of the Bcl2a1 locus in the mouse genome.
14 A1-knockdown studies using in vivo expression of shRNAs in the haematopoietic system suggested a role for A1 in mast cell maturation, 15 mature B cell survival 8 and early T cell development, 16 although not all of these phenotypes were found across the different mouse models analysed. To unambiguously determine the functions of A1, we developed an A1 knockout mouse strain in which all three functional paralogues of A1 (A1-a, A1-b and A1-d) had been deleted. 17 Interestingly, these A1-deficient mice show little to no abnormalities under steady state conditions. However, these observations might not be totally surprising, given that A1 protein levels are very low in unstimulated cells. 18 Therefore, we investigated a role for A1 in mice that had been challenged with different viral infections. These studies clearly demonstrate that loss of A1 alone does not impair T cell-driven immune responses. It therefore appears likely that A1 has critical overlapping functions with other pro-survival BCL-2 proteins in T cell immune responses.
Results
A1 is predominantly expressed in CD4-single positive thymocytes and memory T cells and is rapidly upregulated on TCR/CD3 stimulation. A1 expression was reported on pre-TCR signalling 19 as well as in doublepositive (DP) thymocytes, 20 and is massively induced on T cell activation. 13 Owing to the absence of a reliable antibody detecting murine A1 at that time, these observations were based mainly on mRNA expression analysis. To test A1 protein levels in thymocyte subsets, we isolated them according to their expression of cell subset markers and performed western blot analysis on these extracts. We could detect robust A1 protein expression only in DN1 and 2 and in SP4 thymocytes and to a lesser extent in DN4 stage thymocytes (Figure 1a ). This was consistent with our quantitative real-time PCR (qRT-PCR) results (Supplementary Figure 1A ). As described previously, BCL-XL expression was highest in DP thymocytes and MCL-1 was expressed throughout all T cell developmental stages. In mature CD4
+ and CD8 + splenic T cells, A1 was predominantly expressed in CD62L −
CD44
+ memory-like T cells but was barely detectable in naive T cells (Figure 1b) , agreeing with our qRT-PCR data (Supplementary Figure 1B) . Interestingly, less A1 protein was detected in FoxP3 + Tregs compared with conventional T cells (Figure 1c) .
Furthermore, we isolated CD4 + and CD8 + T cells from the spleens of wild-type mice and stimulated them in culture with anti-CD3 and anti-CD28 to mimic antigenic activation. We confirmed rapid A1 induction at the protein (Figure 1d ) as well as the mRNA level (Supplementary Figure 1C) . Regarding the other pro-survival BCL-2 family members, BCL-2 protein and mRNA levels did not change after TCR/CD3 stimulation, while the amount of MCL-1 protein increased. BCL-XL mRNA and protein levels both increased over the time of TCR/CD3 stimulation, although at a slower rate compared with A1 ( Figure 1d and Supplementary Figure 1C) .
These findings reveal that A1 is weakly expressed throughout T cell development in the thymus and in resting peripheral T cells but is upregulated on antigen-receptor stimulation.
A1
− / − T cells show normal responses on acute infection with influenza virus in a haematopoietic chimaeric setting. As A1 expression was rapidly induced in T cells on activation, we investigated whether the lack of A1 would impair T cell immune responses in a viral infection model. To avoid possible premature death of A1 − / − mice due to impaired anti-viral immunity, we generated mixed bonemarrow chimaeric mice (C57BL/6-Ly5.1 wild-type: C57BL/6-Ly5.2 A1 − / − 1:1) and infected them intra-nasally with the influenza strain HKx31 (Figure 2a ). Another advantage of mixed bone-marrow chimaeras is that we can detect putative competitive disadvantages of A1 −/− lymphoid cells on activation and can therefore directly compare wild-type and A1 −/− T cells responding to viral challenge within the same animal. After 8 days of infection, lungs, mediastinal LN (mLN), and spleens were isolated and analysed by flow cytometry. First, we compared the Ly5.1 to Ly5.2 ratio among CD4 + T cells, CD8 + T cells, and B cells in the spleen to the respective cell types in the blood 5 weeks after reconstitution. Figure 2A) . Importantly, the numbers of the most abundant T cell subset in the lungs, the effector-like memory T cells (T EM ), were comparable between A1 −/− and wild-type origin ( Figure 2c ). Moreover, the frequencies of total CTLs in the spleen was comparable between the wild-type and A1 −/− compartments ( Figure 2d ). Approximately 5% of CTLs were NP-specific for both the T cells of A1 −/− and wild-type origin ( Figure 2d ). In addition, the frequencies of T EM and T CM CTLs were comparable between those of A1 −/− and wild-type origin ( Figure 2d Collectively, these findings show that A1 −/− lymphocytes are able to mount a normal immune response to infection with influenza even in competition with wild-type T cells within the same animal. Apart from a slight reduction in lung infiltrating T CM in the A1 −/− population compared with their wild-type counterparts, no impact of loss of A1 could be observed in any haematopoietic cell type analysed.
−/− mice show normal T cell immune responses to chronic infection with lymphocytic choriomeningitis virus docile. Next, we examined the impact of A1-deficiency on T cell immune responses in a chronic virus infection model. A1
−/− and wild-type mice were infected with lymphocytic choriomeningitis virus (LCMV) docile, which cannot be cleared and eventually leads to exhaustion of CTLs. 21 Eight days post infection, mice were killed and their spleens analysed. The total cellularity of the spleens was comparable between wild-type and A1 −/− mice (Supplementary Figure 3A) , and we clearly observed an enrichment of CTLs in mice of both genotypes (Figure 3a and Supplementary Figure 3B Next, we analysed antigen-specific CTLs by staining with class I MHC tetramers loaded with GP33 or NP396 peptides; allowing discrimination between low-affinity and high-affinity antigen-specific T cells, respectively. No differences in the numbers and frequencies of low-or high-affinity CTLs could be observed between infected A1 −/− and wild-type mice (Figure 3d and Supplementary Figure 3E) . To assess whether A1-deficient antigen-specific T cells were capable of producing IFN-γ in an in vitro recall response, total splenocytes from infected animals were stimulated overnight with GP33 or NP396 peptides before cytokine production was analysed by intracellular flow cytometry. No differences in the frequencies and numbers of IFN-γ-producing T cells was observed between splenocytes from infected A1 −/− versus wild-type mice (Figure 3e and Supplementary Figure 3F) . Finally, we analysed the load of LCMV in the spleen, liver, kidney, lung and brain of infected mice. No differences in viral titres were noted between wild-type and A1
−/− mice ( Figure 3f and Supplementary Figure 3G) .
On the basis of these findings we conclude that loss of A1 does not impair the activation or expansion of CTLs in a chronic infection model of LCMV Docile.
A1-deficient T cells show normal memory responses and expand normally on repeated challenge with influenza virus in vivo. In a separate study, we found that unchallenged A1 −/− mice have slightly reduced numbers of memory T cells compared with their wild-type counterparts. 17 Therefore, we analysed the impact of A1-deficiency in memory T cell formation. Hence, mice were infected intra-nasally with influenza HKx31 virus and memory T cells were enumerated 41 days after infection. First, we analysed the intrinsic ability of A1 −/− CTLs to generate long-lived memory T cells by infecting BM chimaeras (Figure 4 and Supplementary  Figure 4) . After 41 days, comparable frequencies of antigen-specific memory CTLs could be found in the wildtype and A1 −/− compartments (Figure 4a) . Furthermore, the frequencies of A1 −/− T CM and T EM CTLs were comparable (Figure 4a ), as were the frequencies of Tregs (Figure 4b) .
To test for possible extrinsic effects on CD8 + memory T cell formation, intact A1 −/− and wild-type mice were infected with influenza virus. No differences in the memory profile of CTLs in the spleen (Figure 4c) were observed. Moreover, the numbers of NP-specific CTLs were equivalent between the infected wild-type and A1 −/− mice (Figure 4d ). Finally, loss of A1 did not appear to impair the development of CD4 + memory T cells (Figure 4e) .
Next, we investigated whether A1 has a role in the reactivation of memory T cells. C57BL/6-Ly5.2 + wild-type and A1
−/− mice were infected with influenza virus and killed after 41 days. CTLs were enriched by magnetic bead purification and 2 × 10 4 NP-specific A1-deficient or wild-type T cells were transferred into naive C57BL/6-Ly5.1 + (wild-type) recipient mice (Figure 5a ). These mice were challenged with influenza virus one day later and analysed 8 days post infection. We readily identified Ly5.2 + donor-derived T cells in the spleen, mLN and lungs. No differences were observed between mice transplanted with either wild-type or A1 −/− memory T cells (Figure 5b ). In the lungs~20% of the −/− CTLs was observed at the time points tested (Figure 5e ). We were unable to assess BCL-XL by flow cytometry due to the relatively poor quality of these antibodies. Moreover, these cells could not be isolated in sufficient numbers to perform Western blot analysis. Interestingly, Ly5.2 wild-type CTLs showed a slight increase in MCL-1 protein levels, which was not observed in A1 −/− CTLs. BCL-2 expression was reduced in both Ly5.2 + wild-type and A1 −/− CTLs.
Collectively, these findings demonstrate that A1 is dispensable for CD8 + memory T cell formation, expansion and function.
T-helper cell function and B cell responses are not impaired in A1
−/− mice immunised with NP-KLH/Alum. Influenza and LCMV infection primarily activate CTLs, but CD4 + T-helper cells and B cells also participate in the clearance of viruses and other pathogens. 22 To address whether A1 might have an impact on Tfh cells or the formation of GC B cells and long-lived PC, A1 −/− and wildtype mice were immunised with NP-KLH/Alum and analysed 14 days later by flow cytometry. Total spleen cellularity was similar between wild-type and A1 −/− mice (Figure 6a ). The total numbers of Tfh were slightly although not significantly reduced in A1 −/− mice (Figure 6b ). The frequencies and numbers of antigen-specific Ig class-switched GC B cells were comparable between immunised A1 −/− and wild-type mice (Figure 6c ). This indicates that the slight reduction of Tfh cells observed in A1 −/− mice might not be physiologically relevant. The total numbers of PC were slightly but not significantly reduced in the immunised A1-deficient mice compared with their wild-type counterparts (Figure 6d) . To enumerate the antigen-specific PC in the spleen and bone These results show that A1 on its own is not critical for the development of Tfh as well as GC B cells and PC during a T cell-dependent humoral immune response.
Discussion
We show that loss of A1 does not impair T cell immunity in a diverse set of experimental systems. We therefore conclude that A1 does not exert a unique role in T cells or B cells during immune responses. It remains possible that A1 has overlapping roles with other pro-survival BCL-2 family members controlling lymphocyte homoeostasis and activation.
The lack of an obvious phenotype was unexpected, as the levels of A1 mRNA and protein were both rapidly increased in T cells on TCR/CD3 ligation or stimulation with mitogens 17, 18, 23 A1 induction has been defined as a central step in rewiring the cell survival machinery in T cells during the transition from a resting to an activated state. This is associated with a change from a cytokine receptor (mainly IL-7R) to a TCR-driven survival programme and includes the induction of BCL-XL and A1, accompanied by a downregulation of BCL-2.
3 Therefore, it was surprising that A1 −/− mice had no difficulties in clearance of an acute viral infection. Interestingly, T cell-specific loss of BCL-XL, which is also strongly induced on TCR/CD28 stimulation, 24 does not impair T cell responses to Listeria monocytogenes infection and humoral immune responses. 10 This may suggest functional redundancy between these two BCL-2-like proteins.
Besides exhaustion and subsequent inactivation of CTLs, BID-and BIM-dependent apoptosis occurs during persistent viral infection to regulate T cell shutdown. 25 Therefore, we examined whether A1 might be involved in the response to chronic LCMV infection. Surprisingly, we found neither a role for A1 in the overall immune response nor in the survival of high-as well as low-affinity T cell populations. These findings demonstrate that A1 is not essential for the development and survival of CTLs during persistent viral infection or for the preferential survival of high-affinity TCR bearing T cell clones. Our data further strengthen the notion that MCL-1 appears to be the only pro-survival BCL-2 family member that cannot be substituted by other BCL-2 pro-survival family members during T cell activation.
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A1 is readily detectable in memory T cells, and unchallenged A1 −/− mice display a slight reduction in CD4 + memory T cells. 17 These observations suggested a role for A1 as a survival factor for long-lived memory T cells that are still present after the termination of an anti-viral immune response. Although it has been shown that the BIM/BCL-2 axis is a main regulator of the formation and maintenance of memory T cells, 26, 27 NOXA has also been proposed to have a role in regulating the size and clonal diversity of memory T cell populations. 5, 28 This is of particular interest as NOXA, like A1, is induced transcriptionally after TCR ligation. 5 NOXA is believed to antagonise MCL-1 to set a threshold for the survival of those CTLs with high-affinity TCRs. 5 Accordingly, Noxa −/− mice have a higher number of antigen-specific CTLs and an increased memory compartment with higher clonal diversity on infection with influenza. 28 A1 is the closest prosurvival relative to MCL-1 and the only other described highaffinity binding partner of NOXA. 29 Although we could not observe any defects in the generation of antigen-specific memory T cells in response to influenza infection in A1 mice, we cannot exclude that the clonal repertoire of A1 −/− T cells differs from that of wild-type T cells.
It will be interesting to test whether A1 loss can enhance the gene dosage-dependent phenotypes noted in mice lacking one allele of Mcl-1. 30, 31 Along this line it is worth mentioning that such unilateral functional redundancy was also reported in mice that lack the BH3-only protein BMF on a BIM-deficient background. Bmf −/− lymphocytes, such as pre-B cells, showed no or only minor resistance to apoptotic stimuli, but this resistance was massively increased on additional loss of even only one allele of Bim, exceeding resistance observed in Bim −/ − cells. 32 Given that Tregs require continuous TCR signalling for their maintenance and function, 33 it was surprising that we did not observe higher A1 protein levels in Tregs when compared with conventional T cells (Tcons). It has been reported that A1 mRNA levels are high in splenic Tregs but even higher in thymic Tregs when compared with the expression observed in CD4 + Tcons. 34 However, this was not demonstrated at the protein level in this study. Our results nonetheless support similar or even lower protein expression levels of A1 in Tregs compared with Tcons. Therefore, we can only speculate that tonic TCR signalling as received by Tregs leads to the posttranslational downregulation of A1, which is only visible at the protein level. Indeed, it has been shown before that A1 is tightly regulated by ubiquitin-dependent proteasomal degradation. 18, 35 Future experiments of A1 protein stability in Tregs will show whether this hypothesis holds true. Interestingly, non-challenged A1 −/− mice displayed a slight reduction in Tregs compared with wild-type mice. 17 However, this small difference was abolished on viral infection. This may imply a role for A1 in the survival of Tregs under homoeostatic conditions. Alternatively, after TCR/CD3 stimulation, Treg cell survival might depend exclusively on MCL-1. 36 Using a conditional RNAi mouse model to knockdown A1 expression, Carrington et al. 37 showed that conventional DCs (cDCs), which are critical for certain immune responses, rely on A1 for their survival. Schenk et al. 17 also demonstrated that A1-deficient mice have reduced numbers of cDCs. However, the normal immune response of A1 −/− mice to viral infections observed here leads us to the question whether A1 may only be an auxiliary to MCL-1 in cDC survival or whether there are A1-independent antigen-presenting cells that can take over the control of CTL-mediated immune responses in A1 −/− mice. This question remains to be further investigated. It is also noteworthy that the above mentioned and other RNAi-based A1-knockdown mouse models did not show any reductions in the numbers of mature, naive T cells or defects in T cell activation in culture. The lack of a T cell defect was originally ascribed to incomplete knockdown of A1 in activated T cells, 8, 15 but our analysis here points towards functional redundancy between A1 and other pro-survival BCL-2 family members in the survival of quiescent as well as activated T cells.
In conclusion, we showed that A1 ablation is not sufficient to impair viral T cell immune responses in mice. It is, however, interesting that although A1 and BCL-XL are both highly induced in T cells in response to TCR and co-stimulatory signals that contribute to T cell survival, [38] [39] [40] the loss of neither impairs T cell function. This leaves the possibility that A1 and BCL-XL act in a redundant manner or are only of minor importance compared with the highly potent survival protein MCL-1. These questions can now be addressed by the generation of compound mutant mice lacking A1 and/or BCL-XL, BCL-2 and/or MCL-1 in mature T cells.
Materials and Methods
Mice. All experiments with mice were conducted according to the guidelines of The Walter and Eliza Hall Institute of Medical Research Animal Ethics Committee.
A1
−/− mice were generated on a C57BL/6 background. 17 Mice used for in vivo experiments were all 6-10 weeks of age. Bone-marrow (BM) chimaeras were generated by reconstitution of lethally irradiated recipient mice (two doses of 5.5 Gy, 3 h apart) with a mixture of A1 −/− or wild-type bone marrow (Ly5.2) and isogenic wild-type bone marrow (Ly5.1). Mice were analysed 8-12 weeks post reconstitution.
Foxp3
YFP-cre mice 41 were used for sorting wild-type Treg cells based on YFP expression.
In vitro T cell activation. CD4 + and CD8 + T cells were FACS-sorted from spleens of wild-type mice and cultured in RPMI1640 medium supplemented with 10% foetal calf serum (FCS, PAA, Pasching, Austria, FBS Gold #A15-151), 2 mM l-Glutamine, 1% Penicillin plus Streptomycin (10.000 U/ml Penicillin, 10 mg/ml Streptomycin in 0.9% NaCl) and 50 μg/ml Gentamicin. T cells were activated with 5 μg/ml plate-bound anti-CD3 (BioLegend, San Diego, CA, USA, clone 145-2C11) and 1 μg/mL anti-CD28 (BioLegend, clone 37.51) antibodies for the indicated time points.
LCMV infection. LCMV infections were performed by injection of 2 × 10 6 pfu LCMV docile into the tail vein of mice. The origin and biology of LCMV docile has been described. 21 This virus was propagated in L929 cells. To analyse the cytokine production in response to restimulation of LCMV-specific cells, 1 × 10 6 total splenocytes were cultured overnight in the presence of 10-8 M LCMV GP33 (sequence KAVYNFATM), LCMV NP396 (sequence FQPQNGQFI), or non-stimulatory adenovirus (SGPSNTPPEI) in the presence of the protein transport inhibitor Monensin (BD Biosciences, Franklin Lakes, NJ, USA) and stained thereafter for cytokine production as described below.
Viral titres were analysed using the LCMV focus forming assay as described before. 42 In short, brain, liver, lung, spleen and kidney were collected in MEM 2% FCS and frozen at − 80°C before further analysed. Organs were homogenised and supernatant dilutions were used to infect monolayers of MC57 cells (8 × 10 5 per ml), Cells were overlayed with 2% methyl cellulose (Fluka #64620) in DME and plates were incubated at 37°C, 5% CO 2 for 48 h. Viral plaque staining was performed after fixation of the cells with 4% Formalin-PBS and permeabilization with 0.1% Triton X (FLUKA #93418) with VL-4 rat anti-LCMV monoclonal antibody (WEHI Antibody Facility, Melbourne, VIC, Australia) followed by Peroxidase-conjugated AffiniPure goat anti-rat IgG (H+L) antibodies (Jackson ImmunoResearch Laboratories, West Grove, PA, USA #112-035-003). A colour-reaction of ortho-phenylendiamin (Sigma-Aldrich, Pty. Ltd. Sydney, Australia, #P3888) substrate was used for detection of focus forming units. The focus forming unit was used to calculate the viral titre in the original supernatant.
Influenza HKx31 Infection. Mice were lightly anaesthetised by inhalation of methoxyflurane, and infected i.n. with 3000 pfu of HKx31 (H3N2) influenza virus 43 in 25 μl PBS. Virus stocks were grown in the allantoic cavity of 10 day old embryonated chicken eggs, from which the viral titre was determined by plaque assay on monolayers of Madin Derby canine kidney (MDCK) cells.
Infiltrates from the lung were isolated as follows: lungs were mashed through 70 μm cell strainers (BD Biosciences, Cat# 352350) and washed with PBS. Pellets were resuspended in 5 ml PBS supplemented with 2% FCS and underlayed with 3 ml Histopaque 1083 (Sigma, Cat# 1083-1) followed by 30 min centrifugation at 400xg at room temperature with the brakes set off. Mononuclear cells were isolated from the opaque interface and washed extensively with PBS. Staining for cell surface and intracellular markers was performed as described below.
Enrichment of CD8
+ CTLs for influenza rechallenging model. For the enrichment of CD8 + CTLs from spleens of infected mice, splenocytes were incubated with supernatants from hybridoma clones producing the following mABs (WEHI, Antibody Facility, Melbourne, VIC, Australia): rat anti-B220, rat anti-CD11b, rat anti-GR-1, rat anti-CD4, and rat anti-MHCII. Spleen cells expressing these surface markers were depleted using goat anti-rat IgG antibody conjugated magnetic beads (NEB, Ipswich, MA, USA, Cat# S1433S). Enrichment efficiency was assessed by flow cytometry and 2 × 10 4 NP-specific CTLs were injected in 200 μl PBS i.v. into Ly5.1 wild-type recipient mice.
T lymphocyte-dependent B cell immune responses. Mice were immunised by i.p. injection of 100 μg/20 g body weight of 4-hydroxy-3-nitrophenylacetyl (NP) coupled to Keyhole Limpet Hemocyanin (KLH) at a ratio of 27 : 1 and precipitated onto alum. 44 Mice were sacrificed 14 days post immunisation and spleen and bone marrow were isolated for analysis.
Enzyme-linked immunospot assay. The frequency of ASC was determined as described. 44 Briefly, cells were incubated O/N at 37°C on precoated 96-well MultiScreen-HA filter plates (Merck Millipore, Bayswater, VIC, Australia). Spots were visualised with goat anti-mouse IgG1 antibodies conjugated to horseradish peroxidase (Southern Biotechnology Associates, Birmingham, AL, USA), and staining was performed with 3-amino-9-ethyl carbazole (Sigma-Aldrich). Plates were washed extensively, and spots were counted using an AID ELIspot reader system (Autoimmun Diagnostika, Strassberg, Germany).
Western blot analysis. Cells were lysed in lysis buffer (50 mM Tris pH 8, 150 mM NaCl, 0.5% NP-40, 50 mM NaF, 1 mM Na 3 VO 4 , 1 mM PMSF, one tablet protease inhibitors (EDTA free, Roche Austria, Vienna, Austria) per 10 ml and 30 μg/ml DNaseI (Sigma-Aldrich, St. Louis, MO, USA) and protein was quantified with Bradford reagent (500-0006, Bio-Red, Munich, Germany). Overall, 30 μg total protein was loaded on 12% Bis-Tris acryl-amide gels and blotted on AmershamTM HybondTM-ECL nitrocellulose membranes (GE Healthcare, Little Chalfont, UK). The following antibodies were used for protein detection: rat anti-mouse A1 (6D6, 2 μg/ ml), 18 rat anti-BIM (WEHI Antibody Facility, Melbourne, VIC, Australia, clone 3C5, 2.6 μg/ml), mouse anti-HSP90 (F8, Santa Cruz, Dallas, TX, USA, Cat# sc-13119, 0.2 μg/ml), rabbit anti-MCL-1 (polyclonal, Rockland, Limerick, PA, USA, Cat# 600-401-394, 2.2 μg/ml), rabbit anti-BCL-XL (54H6, Cell Signaling, Danvers, MA, USA, Cat# CS2764, 1:1000), rabbit anti-P38 MAPK (polyclonal, Cell Signaling Cat# 9212, 1:1000). All primary antibodies were diluted in 5% BSA in PBST and blots were incubated overnight at 4°C. mRNA purification and qRT-PCR analysis. RNA from approximately 1 × 10 5 cells was isolated, using the Quick-RNA MicroPrep (Zymo Research, Irvine, CA, USA, #R1051) and up to 200 ng RNA was used to generate cDNA using the iScript cDNA Synthesis Kit (Bio-Rad #170-8891).
qRT-PCR was performed using Platinum SYBR Green qPCR SuperMix-UDG reagent (Invitrogen, Waltham, MA, USA) and following primers: A1 fwd 5′ CCTGGCTGAGCACTACCTTC3′; A1 rev 5′TCCACGTGAAAGTCATCCAA3′; Mcl-1 fwd 5′TAACAAACTGGGGCAGGATT3′ Mcl-1 rev 5′GTCCCGTTTCGTCCTTACAA 3′; Bcl-xL fwd 5′TTCGGCATGGAGTAAACTGG3′ Bcl-xL rev 5′TGGATCCA AGGCTCTAGGTG3′; Bcl-2 fwd 5′CTGGCATCTTCTCCTTCCAG3′ Bcl-2 rev 5′ GACGGTAGCGACGAGAGAAG3′; and actin fwd 5′ACTGGGACGACATGGAGAAG 3′ actin rev 5′GGGGTGTTGAAGGTCTCAAA3′. PCR conditions: 7 min 95°C; 40 cycles × (10 s 95°C; 20 s 60°C; 20 s 72°C); 15 s on 95°C; 15 s 60°C; melting curve 20 min; 15 s 95°C. Relative quantification was calculated using the ΔΔ CT method.
